Silence Therapeutics — Third Quarter 2026 Earnings Summary

Silence Therapeutics plc reported a net loss of $12.4 million for the third quarter ended September 30, 2026, driven by $9.3 million in research and development expenses and $4.9 million in general and administrative costs. The company's cash position increased to $247.7 million, which includes $201.3 million in proceeds from a public offering announced in August 2026. Recent business milestones include positive Phase 2 results for the investigational siRNA therapy divesiran in polycythemia vera and the announcement of a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The acquisition transaction is expected to close in the first quarter of 2027, subject to customary closing conditions.